News

FDA has approved Allergan’s ACUVAIL (ketorolac tromethamine ophthalmic solution) 0.45%, a preservative-free formulation of ketorolac. Its a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain and

Peplin has initiated the second non-head phase 3 clinical trial to confirm the efficacy and safety of PEP005 (ingenol mebutate) gel, for the treatment of actinic keratoses (AK).

Open Monoclonal Technology (OMT), in collaboration with Sangamo BioSciences, Sigma-Aldrich, Medical College of Wisconsin, and INSERM, has created the first targeted knockout rats as detailed in Knockout Rats

Following the review of the available evidence on Sanofi-aventis’ Lantus (insulin glargine [rDNA] injection), the European Medicines Agency’ Committee for Medicinal Products for Human Use (CHMP) has confirmed

Columbia Laboratories has signed an agreement with PharmaBio under which Columbia can extend its final royalty payment on sales of STRIANT from November 2010 to November 2011. The

Germany-based, Merck has announced a steady group total revenues in the second quarter and in the first half of 2009 at E1902m and E3756m respectively. Company also posts

Speharm, Access’ European partner, is collecting data from a post approval study of MuGard in head and neck cancer patients, undergoing radiation treatment in the UK showing prevention

The Department of Commerce recently held an invitation-only meeting in order to reach out to industry to discuss international climate change negotiations. Numerous governmental agencies are involved in

Repros Therapeutics has provided a clarification on the occurrence of increased liver enzymes in patients treated with the 50mg dose of Proellex. Repros’ recent decision to discontinue the